Cargando…

Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting

INTRODUCTION: Type 2 diabetes represents a continuing healthcare challenge, and choosing cost-effective treatments is crucial to ensure that healthcare resources are used efficiently. The present analysis assessed the cost-effectiveness of once-weekly semaglutide 1 mg versus empagliflozin 25 mg for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Capehorn, Matthew, Hallén, Nino, Baker-Knight, James, Glah, Divina, Hunt, Barnaby
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846640/ https://www.ncbi.nlm.nih.gov/pubmed/33423240 http://dx.doi.org/10.1007/s13300-020-00989-6

Ejemplares similares

The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK
por: Viljoen, Adie, et al.
Publicado: (2022)

Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK
por: Johansen, Pierre, et al.
Publicado: (2020)

Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Liraglutide 1.8 mg: A Health Economic Analysis in the UK
por: Evans, Marc, et al.
Publicado: (2023)

The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain
por: Vidal, Josep, et al.
Publicado: (2020)

A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK
por: Johansen, Pierre, et al.
Publicado: (2020)

Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting
por: Stafford, Sara, et al.
Publicado: (2022)

Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis
por: Lingvay, Ildiko, et al.
Publicado: (2020)

Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme
por: Bain, Stephen C., et al.
Publicado: (2019)

Correction to: Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canaglifozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting
por: Stafford, Sara, et al.
Publicado: (2022)

Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in the United Kingdom
por: Sandhu, Hera, et al.
Publicado: (2023)

Evaluation of the long‐term cost‐effectiveness of once‐weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK
por: Viljoen, Adie, et al.
Publicado: (2018)

Once-weekly 2.4 mg Semaglutide for Weight Management in Obesity: A Game Changer?
por: Colin, Ides M, et al.
Publicado: (2022)

Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands
por: Hunt, Barnaby, et al.
Publicado: (2019)

The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal
por: Malkin, Samuel J. P., et al.
Publicado: (2022)

A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving Basal Insulin
por: Witkowski, Michal, et al.
Publicado: (2018)

Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia
por: Malkin, Samuel J. P., et al.
Publicado: (2018)

Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide 2.4 MG in Adults With Overweight or Obesity (STEP 1)
por: Wilding, John P H, et al.
Publicado: (2021)

The Impact Once-Weekly Semaglutide 2.4 mg Will Have on Clinical Practice: A Focus on the STEP Trials
por: Alabduljabbar, Khaled, et al.
Publicado: (2022)

Once‐weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long‐term cost‐effectiveness analysis based on SUSTAIN 11
por: Evans, Marc, et al.
Publicado: (2022)

A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1–2 Oral Anti-Diabetic Drugs
por: Witkowski, Michal, et al.
Publicado: (2018)

The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia
por: Malkin, Samuel J. P., et al.
Publicado: (2019)

The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity
por: Friedrichsen, Martin, et al.
Publicado: (2021)

Efficacy and Safety of Semaglutide 2.4 MG Once-Weekly in Adults With Overweight or Obesity and Type 2 Diabetes (STEP 2)
por: Davies, Melanie, et al.
Publicado: (2021)

Modeling the Long-Term Cost-Effectiveness of IDegLira in Patients with Type 2 Diabetes Who are Failing To Meet Glycemic Targets on Basal Insulin Alone in The Netherlands
por: Hunt, Barnaby, et al.
Publicado: (2017)

Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
por: Johansen, Pierre, et al.
Publicado: (2019)

Weight Loss Maintenance With Once-Weekly Semaglutide 2.4 MG in Adults With Overweight or Obesity Reaching Maintenance Dose (STEP 4)
por: Rubino, Domenica M, et al.
Publicado: (2021)

Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program
por: Perreault, Leigh, et al.
Publicado: (2022)

An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression
por: Lingvay, Ildiko, et al.
Publicado: (2021)

Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States
por: Wilkinson, Lars, et al.
Publicado: (2018)

Abstract 10: Efficacy and safety of semaglutide 2.4 mg once- weekly in adults with overweight or obesity and type 2 diabetes (STEP 2)
por: Rahman, Syed Kasfur, et al.
Publicado: (2022)

Once-weekly Subcutaneous Semaglutide 2.4 mg Reduces Body Weight in Adults with Overweight or Obesity Regardless of Baseline Characteristics (STEP 1)
por: Kushner, Robert F, et al.
Publicado: (2021)

Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss
por: Wharton, Sean, et al.
Publicado: (2021)

Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting
por: Gæde, Peter, et al.
Publicado: (2019)

Clinically-Relevant Weight Loss is Achieved Independently of Early Weight Loss Response to Once-Weekly Subcutaneous Semaglutide 2.4 MG (STEP 4)
por: Mosenzon, Ofri, et al.
Publicado: (2021)

An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg
por: Pratley, Richard E., et al.
Publicado: (2021)

Abstract 9: Once-weekly subcutaneous semaglutide 2.4 mg reduces body weight in adults with overweight or obesity regardless of baseline characteristics (STEP 1)
por: Suresh, Swaroop H, et al.
Publicado: (2022)

A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA
por: Johansen, Pierre, et al.
Publicado: (2019)

A model‐based simulation of glycaemic control and body weight when switching from semaglutide to 3.0‐ and 4.5‐mg doses of once‐weekly dulaglutide
por: Tham, Lai San, et al.
Publicado: (2021)

Correction to: A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA
por: Johansen, Pierre, et al.
Publicado: (2019)

Correction: Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8kddeog17lbsaqg633acrrt12g